X4 Pharmaceuticals

X4 Pharmaceuticals is developing a novel therapy aimed at enhancing immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company’s oral small-molecule candidate antagonizes the CXCR4 pathway, which plays a central role in immune surveillance.